Radiopharm Theranostics has scheduled an End-of-Phase 2 meeting with the FDA for October 1, 2026, to discuss the pivotal Phase 3 trial design for RAD101, an imaging agent for recurrent brain metastases. This meeting is a critical step towards a registrational study, building on strong Phase 2b data and a recent partnership with Siemens Healthineers for manufacturing and distribution.
Radiopharm Theranostics announced a significant milestone by securing an End-of-Phase 2 meeting with the FDA for RAD101, scheduled for October 1, 2026. This meeting is crucial for aligning on the design of a pivotal Phase 3 trial for their novel imaging agent, which targets recurrent brain metastases. The positive Phase 2b data, showing 93% concordance with MRI, and the recent partnership with Siemens Healthineers for manufacturing and distribution, underscore the potential of RAD101 to address a significant unmet medical need. For traders, this represents a long-term positive catalyst for Radiopharm Theranostics, as successful progression through Phase 3 and subsequent approval could unlock substantial value. The primary risk is any delay or unfavorable outcome from the FDA meeting, which could impact the timeline and design of the Phase 3 trial.